4D Molecular Therapeutics (NASDAQ:FDMT) Insider David Kirn Sells 12,415 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 12,415 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $10.05, for a total transaction of $124,770.75. Following the sale, the insider owned 871,737 shares in the company, valued at $8,760,956.85. The trade was a 1.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

David Kirn also recently made the following trade(s):

• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.03, for a total transaction of $189,171.75.
• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.87, for a total transaction of $548,364.96.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62.
• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $19,258.44.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock opened at $10.26 on Wednesday. The stock has a market capitalization of $536.39 million, a price-to-earnings ratio of -3.99 and a beta of 2.73. The company’s fifty day simple moving average is $10.64 and its two-hundred day simple moving average is $9.69. 4D Molecular Therapeutics, Inc. has a 1 year low of $5.23 and a 1 year high of $14.00.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The company had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. Equities research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. The Goldman Sachs Group set a $33.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, May 8th. B. Riley Financial initiated coverage on shares of 4D Molecular Therapeutics in a research report on Friday, July 31st. They issued a “buy” rating and a $37.00 price objective for the company. Finally, Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.67.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Exome Asset Management LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 1st quarter valued at about $1,216,000. Evergreen Quality Fund GP Ltd. purchased a new position in shares of 4D Molecular Therapeutics during the fourth quarter worth about $7,136,000. Simplify Asset Management Inc. purchased a new position in shares of 4D Molecular Therapeutics during the first quarter worth about $656,000. Janus Henderson Group PLC increased its position in shares of 4D Molecular Therapeutics by 13.2% in the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after purchasing an additional 611,276 shares during the last quarter. Finally, Baker BROS. Advisors LP bought a new position in shares of 4D Molecular Therapeutics in the fourth quarter worth approximately $3,568,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.